- Details
- Description
-
Packaging Size28t
-
Strength40mg
-
CompositonFurmonertinib Mesilate
-
TreatmentNSCLC：non-small cell lung cancer with positive EGFR T790M mutation
-
FormTablet
-
BrandIvesa (艾弗沙)
-
Quantity Unit40mg*28t/Box
-
ManufacturerAllist Pharmaceuticals,china
About Furmonertinib
Furmonertinib Mesilate acts as an anti-cancer agent. It is formulated as tablets for oral route of administration. Furmonertinib is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive EGFR T790M mutation.
- Furmonertinib sold under the brand name Ivesa.
- Furmonertinib sold under the brand name 艾弗沙 in china.
Approval
June/2022, Shanghai Allist Pharmaceuticals Co., Ltd. (stock code: 688578) announced that Furmonertinib had been approved by the National Medical Products Administration (NMPA) of China for use in the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations.
Dosage
The recommended dose of this product is 80 mg, taken orally once a day until disease progression or intolerable toxicity occurs.
This product should be taken on an empty stomach. Take this product at approximately the same time every day, swallow the whole tablet with water, do not crush or chew. If the patient misses a dose of this product and it is more than 12 hours before the next dose, the patient should take this product.
Dosage adjustment
If adverse events occur during the use of this product, the drug can be temporarily interrupted, the dose can be reduced, or the treatment with this product can be stopped according to the specific situation. If a reduction is required, the dose can be reduced to 40 mg, once a day.
